T06020" 2540760



FIG. 1A RELAXIN



FIG. 1B RELAXIN





FIG. 1C RELAXIN



FIG. 1D RELAXIN



FIG. 2A



FIG. 2B



FIG. 2C



FIG. 2D



FIG. 3A



FIG. 3B



FIG. 3C



FIG. 3D



FIG. 4A



FIG. 4B



FIG. 4C



FIG. 4D


Sham
Sham + RLX
Infarct + Vehicle
Infarct + RLX
Relative mRNA Expression
14
12
10
8
6
4
2
0
VEGF 164
VEGF 120
bFGF
VEGF 164
VEGF 120
bFGF
Day 7
Day 21

FIGURE 5


Relative mRNA Expression
VEGF 165
VEGF 121
bFGF
0
1
2
3
4
0 1 10 100
0
Normoxia
Hypoxia
Relaxin
(ng/ml)

FIGURE 6



* $p<0.05$ compared to veh-hyp; ↑ $p<0.01$ compared to veh-hyp

FIG. 7

FIGURE 8A





FIGURE 8B


Relaxin (ng/ml)
0
0.1
1
10
Relative mRNA Expression/GAPDH
3.5
3
2.5
2
1.5
1
0.5
0
V 165
V121
bFGF

FIGURE 9

T06020 "35203826D

FIGURE 10



* p<0.05

**p<0.02

FIGURE 11


Placebo
25 ug/kg-day
Systolic Blood Pressure
RLXN.C.005
Change in Systolic Blood Pressure from Baseline
2
1
0
-1
-2
-3
-4
-5
-6
-5
0
5
10
15
20
25
30
Weeks
*
**
#
* p<0.05
**p<0.02
# p<0.001

T06020 * 25/08/60

FIGURE 12



 # p<0.02

*** p<0.05**

(10 ug/kg-day vs. baseline)

T06020 "35208260

FIGURE 13



* p<0.05

# p<0.02


Myogenic Reactivity of Small Renal Arteries
Relaxin-Treated Rats (n=6)
Vehicle-Treated Rats (n=5)
% Change from Dm @ 20 mmHg
60
50
40
30
20
10
0
-10
-20
0
20
40
60
80
100
120
Pressure (mm Hg)
p=0.026

FIGURE 14


Myogenic Reactivity of Small Mesenteric Arteries
Relaxin-Treated Rats (n=5)
Vehicle-Treated Rats (n=6)
% Change from Dm @ 20 mmHg
50
40
30
20
10
0
-10
-20
-30
0
20
40
60
80
100
120
140
Pressure (mm Hg)
p=0.006

FIGURE 15